AtaiBeckley Inc. ATAI 深 滬

美股大行评级 | 存储再获看多！美光、闪迪、西部数据获机构上调目标价；次新股Cerebras、Blackstone、EagleRock获多家机构首予买入平均

今日重点评级关注：Ascendiant Capital：维持IGC Pharma"买入"评级，目标价从5.25美元升至5.5美元；Ascendiant Capital：维持Lucid Diagnostics"买入"评级，目标价从9美元升至9.25美元

06-09 11:33

HC Wainwright & Co. Reiterates Buy on AtaiBeckley, Maintains $25 Price Target

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates AtaiBeckley (NASDAQ:ATAI) with a Buy and maintains $25 price target.

06-08 18:30

AtaiBeckley Launches Patient Impact Grant Program for Mental Health Non-Profit Organizations

AtaiBeckley Inc. has launched the Patient Impact Grant Program, offering three $20,000 grants to non-profit organizations focused on community support, education, stigma reduction, and mental health research. Applications are open until September 1.

05-28 13:00

AtaiBeckley to Participate in Upcoming Investor Conferences in June 2026

AtaiBeckley Inc. announced that its management team will participate in multiple investor conferences in June 2026, including the Jefferies Global Healthcare Conference in New York, the Oppenheimer CNS and Neuro-Muscular Summit in Miami, the 7th Annual HCW Neuro Perspectives Hybrid Conference, and the UBS Virtual CNS Day. The company, focused on developing rapid-acting mental health treatments, will present its pipeline, including BPL-003, VLS-01...

05-27 10:00

AtaiBeckley Q1 EPS $(0.08) Beats $(0.11) Estimate, Sales $954.000K Beat $11.111K Estimate

AtaiBeckley (NASDAQ:ATAI) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.11) by 27.27 percent. This is a 46.67 percent increase over losses of $(0.15) per share from the

05-12 20:10

AtaiBeckley Reports First Quarter 2026 Financial Results and Provides Program and Business Update

AtaiBeckley Inc. reported Q1 2026 financial results and business updates, including BPL-003 Phase 3 initiation in Q2 2026, VLS-01 Phase 2 results expected in Q4 2026, and positive EMP-01 Phase 2a data for Social Anxiety Disorder. Cash of $209.9M is expected to fund operations through 2029. The company also announced its inclusion in the S&P Biotechnology Select Industry Index and appointed Michael Faerm as CFO.

05-12 12:00

'Health Officials Close To U.S. Secretary Kennedy Explored Ban Of Some Widely Used Antidepressants' - Reuters Exclusive

Health officials explored restricting specific antidepressants among SSRI drugs-sourcesKennedy announced other steps to reduce use of the medicines on MondayKennedy says SSRIs are overprescribed and, without evidence,

05-09 00:02

10 Health Care Stocks With Whale Alerts In Today's Session

This whale alert can help traders discover the next big trading opportunities. ...

05-02 01:35

AtaiBeckley and PsyPAN Receive a Silver Award in 2026 Patient Participant Index, Reflecting Ongoing Commitment to Participant-Informed Research

04-27 08:05

AtaiBeckley: Anxiety Drug Cuts Social Phobia Symptoms By 38%

AtaiBeckley reports Phase 2a data for EMP-01 in social anxiety, showing stronger symptom reduction and response rates versus placebo.

04-22 20:11